These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 36830717)

  • 1. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.
    Iyoda T; Yamasaki S; Ueda S; Shimizu K; Fujii SI
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
    Fantini M; Arlen PM; Tsang KY
    Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.
    Mortezaee K; Majidpoor J
    Med Oncol; 2022 Jun; 39(9):131. PubMed ID: 35716327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
    Ghaedrahmati F; Esmaeil N; Abbaspour M
    Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8
    Shimizu K; Ueda S; Kawamura M; Aoshima H; Satoh M; Nakabayashi J; Fujii SI
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37400134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
    Kennedy PR; Felices M; Miller JS
    Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse CD8
    Li Z; Wu Y; Wang C; Zhang M
    Cancer Immunol Immunother; 2019 Aug; 68(8):1303-1315. PubMed ID: 31278476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.
    Krijgsman D; Hokland M; Kuppen PJK
    Front Immunol; 2018; 9():367. PubMed ID: 29535734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
    Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
    Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NKT cells in cancer immunotherapy-from bench to bed.
    Bayatipoor H; Mehdizadeh S; Jafarpour R; Shojaei Z; Pashangzadeh S; Motallebnezhad M
    Med Oncol; 2022 Dec; 40(1):29. PubMed ID: 36460881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment.
    Aoyama S; Nakagawa R; Nemoto S; Perez-Villarroel P; Mulé JJ; Mailloux AW
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.
    Subleski JJ; Wiltrout RH; Weiss JM
    J Autoimmun; 2009; 33(3-4):275-81. PubMed ID: 19682859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.